On October 16, Revolution Medicines, Inc. fell 5.02% in Regular Trading, trading at $179.4831 per share, with turnover of $111 million.
The most recent company-specific catalyst in public reporting was continued analyst optimism around the launch of Rasonque, rather than a newly disclosed negative event. A note published on October 14 said early launch enthusiasm remained strong following the August FDA approval for pancreatic cancer, with patients already converting from the early access program and a strong launch potentially supporting about $36 million in third-quarter revenue.
That followed a series of supportive updates, including RBC raising its price target to $259, BofA maintaining a Buy rating with a $264 target, and the company beginning patient treatment in a Phase 3 trial evaluating Rasonque plus zoldonrasib in first-line metastatic RAS G12D pancreatic cancer. Despite that constructive backdrop, the available information does not identify a fresh negative announcement that fully explains today’s pullback.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments